Taiko Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales to be JPY 6,000 million, operating loss to be JPY 2,800 million, net loss to be JPY 3,300 million and Basic loss per share to be JPY 75.67.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
349 JPY | -0.57% | +0.58% | +15.18% |
1st Jan change | Capi. | |
---|---|---|
+15.18% | 114M | |
+19.98% | 43.48B | |
+20.67% | 22.65B | |
+14.56% | 14.73B | |
+14.32% | 13.79B | |
+44.72% | 12.04B | |
-8.37% | 7.08B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+11.90% | 5.47B |
- Stock Market
- Equities
- 4574 Stock
- News Taiko Pharmaceutical Co.,Ltd.
- Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Year ending December 31, 2022